Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Elan, Inex form JV to develop Onco TCS

Executive Summary

Elan and Inex Pharmaceuticals (targeted chemotherapy; oligonucleotides) have formed a joint venture to develop and market Inex's Onco TCS (vincristine) to treat several types of cancer.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Liposomes
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Includes Equity
    • Joint Venture

Related Companies

Advertisement
UsernamePublicRestriction

Register